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Vascular calcification burden of Chinese
patients with chronic kidney disease:
methodology of a cohort study
Zhi-Hong Liu* and the China Dialysis Calcification Study (CDCS) Group
Abstract
Background: Vascular calcification is a common complication associated with chronic kidney disease and the
major cause of cardiovascular disease in patients with end-stage renal disease. The vascular calcification risk burden
is still unknown in China. This study aims to investigate the prevalence of vascular calcification and assess the
predictive value of vascular calcification in patients with stage 5 chronic kidney disease on dialysis in China.
Methods/Design: This is a national, multicenter, non-interventional, prospective cohort study planning to recruit
1520 patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis for at least 6 months in
24 dialysis centers in China. All the patients provided written informed consents before participating in this study.
It will include a baseline visit and 24 months follow-up period with 4 other visits at 6-month intervals. Vascular
calcification images will be obtained to determine the prevalence of vascular calcification, coronary artery
calcification, abdominal aortic calcification and cardiac valve calcification. Association between vascular calcification
and all-cause and cardiovascular disease mortality and non-fatal cardiovascular events will be assessed. Disease
management, as assessed by serum level of calcium, phosphorus and intact parathyroid hormone and its impact
on vascular calcification, will also be surveyed.
Discussion: The new results gained from this study will supplement limited current available data and provide
better clinical decisions in Chinese patients with chronic kidney disease on dialysis.
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Background
Chronic kidney disease (CKD) is a critical health prob-
lem. It is estimated that there were nearly 120 million
patients with CKD in China with an overall prevalence
of 10.8 % [1]. It is similar to that in the United States
(13.1 %) and Norway (10.2 %) but the awareness of CKD
(10.04 %) is still relatively low in China [2–4]. The num-
ber of patients with end-stage renal disease (ESRD) is
estimated to be 2 million in China, but less than 20 % of
patients are undergoing dialysis [5].
Vascular calcification (VC) is a common complication
associated with CKD and the major cause of cardiovas-
cular disease (CVD) in patients with ESRD [6]. In con-
trast, patients without VC always have a better prognosis
with limited progression of VC over a longer period
of time [7]. The prevalence of VC increases as CKD
progresses, from 40 % at stage 3 CKD to 80–99 % at
stage 5 CKD on dialysis (CKD stage 5D) [8–12].
Mineral and bone disorder (MBD) is also a frequent
complication of CKD associated with increased risk of
VC, arterial dysfunction, morbidity and mortality [13]. A
meta-analysis revealed that every 1.0 mg/dL of serum
phosphorus was associated with 18 % increase of the risk
of death in patients with CKD, indicating that hyperpho-
sphatemia is an independent risk factor for mortality
among those patients [14]. Hyperphosphatemia is in-
creasingly considered the cause and a key factor indu-
cing early and progressive VC in patients with CKD,
implying that vigorous treatment of hyperphosphatemia
with phosphate binders is essential to the prevention of
VC [15, 16]. In addition, hyperphosphatemia is a key
regulator involved in multiple mechanisms that induce
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and promote the progression of VC [15]. Therefore,
prevention of MBD and lowering the circulating levels
of phosphate and calcium have become major targets in
the treatment of VC [17].
MBD management is not optimized for Chinese dialy-
sis patients and hyperphosphatemia is an important
issue needing greater awareness [18]. However, there is
limited knowledge about the impact of VC on Chinese
dialysis patients in current disease management and
dialysis patterns. Additionally, the VC risk burden is still
unknown in China, causing poorer prognosis and inad-
equate dialysis management. The China Dialysis Calcifi-
cation Study (CDCS) is the first large, prospective,
multicenter, observational cohort study to investigate the
prevalence of VC using different non-invasive imaging
techniques and to assess the predictive value of VC with
associated risk factors for all-cause and CVD mortality
in dialysis patients with CKD stage 5D in China.
Methods/Design
Study design
The CDCS is a national, multicenter, non-interventional,
24 month prospective cohort survey in CKD patients on
dialysis. The study includes a baseline visit and 4 other
visits at 6 month intervals. The estimated enrollment
period is 10 months. It is planned to consecutively recruit
1520 patients with ESRD receiving stable hemodialysis
(HD) or peritoneal dialysis (PD) for at least 6 months in
24 dialysis centers in China. Participating centers will be
selected based on logistics constraints. Consecutive pa-
tients who fulfill the inclusion and exclusion criteria and
are willing to participate will be included in the study
(Table 1). Written informed consents were obtained from
all patients before participation. Each site is expected to
enroll approximately 30 patients. After that, enrollment
will be competitive at all sites. This study will be able to
mirror real life management of these patients. All statis-
tical analyses will be performed using SAS 9.2 soft-
ware (SAS Institute, Cary, NC, USA). All hypothesis
tests will use two-sided tests with a significance level
of 0.05.
CKD is defined as abnormalities of kidney structure or
function, present for >3 months, with implications for
health, according to Kidney Disease: Improving Global
Outcomes (KDIGO) 2012 Clinical Practice Guideline for
the Evaluation and Management of CKD (Table 2) [19].
Objectives
The primary objective for the CDCS is to determine the
prevalence of VC in Chinese patients with CKD on HD
or PD. The secondary objectives are:
1. To test the hypothesis that a greater severity of
baseline VC is associated with a higher risk for
all-cause and CVD mortality, and non-fatal CV
events in Chinese patients with CKD on HD or PD.
2. To investigate the association between all-cause and
CVD mortality, and non-fatal CV events and disease
management (using serum levels of calcium,
phosphorus and intact parathyroid hormone (iPTH),
fibroblast growth factor 23 (FGF23) and related
medications) in Chinese patients with CKD on HD
or PD.
3. To investigate the impact of current disease
management on VC.
4. To evaluate the control rate of patients achieving
target goal of serum phosphorus, calcium and iPTH.
5. To validate the cardiovascular calcification index
(CCI) in Chinese patients with CKD on HD or PD.
Data collection
Visit 1 is at baseline/study entry and the follow-up in-
cludes 4 visits at 6 ± 1 month, 12 ± 1 month, 18 ± 1
months and 24 ± 1 month, respectively. The flow chart
of detailed data and sample collection can be found in
Table 3. At baseline, eligible patients will be evaluated
for demographic information, smoking, alcohol drinking
status, biochemical data, dialysis variables, concomitant
medications, and personal and family disease history.
Physical measurements including weight, height, body
mass index (BMI) and vital signs (blood pressure and
heart rate) will be obtained. Older age (male >55 years,
Table 1 Inclusion and exclusion criteria of the CDCS
Inclusion criteria Exclusion criteria
Male or female patients≥18 years old Patients’ life expectancy <6 months
Patients with ESRD receiving stable HD or PD for at
least 6 months
Patients with acute kidney injury, active inflammatory diseases, parathyroidectomy or evident
malignancies
Patient or legally accepted representative willing to
sign Data Release Consent Form.
Patients with conditions making arterial calcification measurements technically impossible or
unreliable, such as cardiac arrhythmias, amputations or severe peripheral vascular lesions
Concomitant diseases that affect calcium status and soft tissue calcifications (sarcoidosis,
multiple myeloma, HIV, amyloidosis)
Pregnant or lactating women or women planning to become pregnant in the 6 months
following entry into the study
ESRD End-stage renal disease, HD Hemodialysis, PD Peritoneal dialysis, HIV Human immunodeficiency virus
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female >65 years), arterial hypertension, family history
(mother, father, brother, sister, children) of premature
cardiovascular disease (≤55 years male, ≤65 years fe-
male), smoking, impaired glucose tolerance and/or
impaired fasting glucose, dyslipidemia, and obesity are
considered potent cardiovascular risk factors. The base-
line biochemical data will be obtained using local routine
laboratory methods performed within a week at the
start of the study. If laboratory tests of serum 25-
hydroxyvitamin D (25-OH Vit D) and FGF23 cannot be
conducted in some centers, blood samples for testing
25-OH Vit D and FGF23 will be sent by the site study
staff to those centers that can perform the assay. Blood
sample collection will be performed according to the la-
boratory manual. Results from routine samples defined
as samples taken within a week at the visit. Serum phos-
phorus, total calcium and iPTH will be tested at each
visit. Target level of serum phosphorus, total calcium
and iPTH in CKD stage 5 are defined according to
Kidney Disease Outcomes Quality Initiative (K/DOQI) and
KDIGO guidelines, respectively (Table 4) [20, 21]. Total
serum calcium is adjusted if serum albumin is <4g/dL to
better reflect the free calcium, using the formula proposed
by the US Bone Metabolism Association: corrected total
calcium (mg/dL) = total calcium (mg/dL) + 0.8 × [4.0 −
serum albumin (g/dL)]. Date, time, primary reason
and characteristics of death with autopsy results if
applicable and any supportive documents that relate
to fatal and nonfatal CV events are defined as
Table 2 Criteria for CKD (either of the following present for
>3 months)
Criteria
Markers of kidney damage
(one or more)
Albuminuria (AER ≧30 mg/24 h; ACR ≧30 mg/g)
Urine sediment abnormalities
Electrolyte and other abnormalities due to
tubular disorders
Abnormalities detected by histology
Structural abnormalities detected by imaging
History of kidney transplantation
Decreased GFR GFR <60 ml/min/1.73 m2 (GFR categories
G3a–G5)
GFR Glomerular filtration rate, AER Albumin excretion rate, ACR
Albumin-creatinine ratio
Table 3 Study flow chart of the CDCS
Procedures Visit time (month)
Baseline 6 ± 1 12 ± 1 18 ± 1 24 ± 1
Data release consent form ●
Demography data ●
Inclusion/exclusion criteria ●
Physical measurements (vital signs) ●
Smoking and alcohol drink status ●
Cardiovascular risk factors ●
Disease history ●
Concomitant medications ● ● ● ● ●
Hemoglobin, hematocrit ●
Serum total calcium, phosphorus, iPTH ● ● ● ● ●
25-OH Vit D, FGF23 ● ● ●
Glucose, HDL-C, LDL-C, TC and TG ●
hs-CRP ●
Serum albumin, ferritin, alkaline phosphatase ●
Urea, uric acid, creatinine ●
ABI ●
Kt/V, dialysate calcium concentration ●
Dialysis vintage, dialysis frequency and modality, membrane type ●
EBCT or MDCT scan ● ●
Plain lateral lumbar radiograph ● ●
Echocardiography, LVMI/LVH ● ●
Clinical outcomes ● ● ● ●
iPTH Intact parathyroid hormone, 25-OH Vit D serum 25-hydroxyvitamin D, FGF23 Fibroblast growth factor 23, HDL-C High density lipoprotein-cholesterol, LDL-C
Low density lipoprotein-cholesterol, TC Total Cholesterol, TG Triglyceride, hs-CRP High-sensitivity C-reactive protein, ABI Ankle-brachial index, EBCT Electron beam
computed tomography, MDCT Multi-detector computed tomography, LVMI Left ventricular mass index, LVH Left ventricular hypertrophy
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clinical outcomes, and will be collected during the
follow-up.
Imaging methods
VC images will be taken within a week of enrolment and
the final visit of the study. Coronary artery calcification
(CAC), abdominal aortic calcification (AAC) and cardiac
valve calcification will be assessed by electron beam
computed tomography (EBCT) or multi-detector com-
puted tomography (MDCT), plain lateral lumbar radio-
graph and echocardiography, respectively. In addition,
results of left ventricular mass index (LVMI) and left
ventricular hypertrophy (LVH) through echocardiog-
raphy will be taken within a week of enrolment and the
final visit of the study as well.
CAC is measured by EBCT or MDCT as originally de-
scribed by Agatston et al. [22]. Thirty to forty contiguous
tomographic slices will be obtained at 3-mm intervals
beginning 1 cm below the carina and progressing caudally
to include the entire coronary tree. An attenuation thresh-
old of 130 Hounsfield units (HU) and a minimum of 3
contiguous pixels will be used for identification of a cal-
cific lesion. The density factor is assigned in the following
manner: 1 for lesions with peak attenuation of 130–199
HU, 2 for lesions with peak attenuation of 200–299 HU, 3
for lesions with peak attenuation of 300–399 HU, and 4
for lesions with peak attenuation >400 HU [22]. Total
CACS is determined by summing individual lesion scores
from each of four anatomic sites (left main, left anterior
descending, left circumflex, and right coronary artery).
The CACS will be divided into approximate tertiles
(0, <100, ≥100, ≥400 and ≥1000). CAC progression is
evaluated as a continuous variable by calculating the
difference in Agatston score between the two CT
scans divided by the time between imaging. The 2-
year progression of CAC is categorized as follows:
absent (≤25th percentile), moderate (25th-75th per-
centiles), and accelerated (≥75th percentile).
AAC is assessed by semiquantitative scoring of a plain
lateral lumbar radiograph using previously validated 24-
point aortic calcification scale as originally described by
Kauppila et al. [23]. Midpoint of the intervertebral space
above and below the vertebrae will be used to assess cal-
cific deposits in the aorta adjacent to each lumbar verte-
bra (L1-L4), and lesion grading is based on a 0–3 scale:
0, no aortic calcific deposits; 1, small scattered calcific
deposits (<1/3 of the longitudinal wall of the aorta); 2,
calcific deposits ≥1/3 and <2/3; 3, calcific deposits ≥2/3
[23]. The scores, obtained separately for the anterior and
posterior wall, result in a range from 0 to 6 for each
vertebral level and 0 to 24 for the total AAC score. The
AAC will be divided into approximate tertiles (0, <5,
and ≥5, ≥16).
Cardiac valve calcification is measured by a standard
two-dimensional M-mode color Doppler echocardiog-
raphy. Cardiac valve calcification will be considered
present when bright echoes of more than 1-mm thick-
ness are seen on 1 or more cusps of the aortic valve,
mitral valve, or mitral annulus. Thereafter, patients are
divided into 3 groups according to number of calcified
valves: patients without valve calcification, patients with
a single (aortic or mitral) valve calcification, and patients
with calcifications in both valves.
LVMI is calculated with echocardiography and nor-
malized to body height as an index in g/m2. LVH is diag-
nosed when LVMI is >125 g/m2 in males or >120 g/m2
in females.
CCI
Points of CCI are assigned for patients age (60–69 and
70 years, 1 and 2 points, respectively), dialysis vintage 2
years (1 point), aortic and mitral valve calcification (3
and 1 points, respectively), and abdominal aorta X-ray
scores of 1–6 and 7 (2 and 4 points, respectively). Race,
sex and pulse pressure do not contribute to the CCI.
Therefore, the CCI ranges from 0 to 11 points.
Demographic and baseline data analysis
Categorical data will be presented in contingency tables
along with frequencies and percentages. Continuous data
will be summarized with frequency (n), mean, standard
deviation, median, 1st quartile, 3rd quartile, minimum and
maximum. Descriptive analyses will be presented by
groups (with VC vs. without VC, with CAC vs. without
VC, with AAC vs. without VC, with cardiac valve calcifica-
tion vs. without VC). For categorical variables, group com-
parison will be based upon the results of the Chi-square
test (for 2 × 2 tables) or the Cochran-Mantel-Haenszel test
(for r × c tables, where r or c is greater than 2). Chi-square
test will be replaced by Fisher’s exact test if the expected
frequency in any of the cells of the contingency table is
less than 5. For continuous variables, group comparison
Table 4 Target level of serum phosphorus, calcium and iPTH in CKD stage 5
Biochemical parameters K/DOQI KDIGO
Serum phosphorus 3.5–5.5 mg/dL (1.13–1.78 mmol/L) Toward Normal [2.5–4.5 mg/dL (0.81–1.45 mmol/L)]
Corrected total calcium 8.4–9.5 mg/dL (2.10–2.38 mmol/L) Maintain Normal [Healthy: 8.5–10.5 mg/dL (2.13–2.63 mmol/L)]
Serum iPTH 150–300 pg/mL (16.5–33.0 pmmol/L) 2–9 times the upper normal limit (65 pg/mL, 6.9 pmmol/L)
K/DOQI Kidney Disease Outcomes Quality Initiative, KDGIO Kidney Disease: Improving Global Outcomes, iPTH Intact parathyroid hormone
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will be based upon the results of the t-test or the
Wilcoxon rank-sum test, depending on the distribution.
Primary analysis
Prevalence of VC at baseline and its corresponding
95 % confidence interval (CI) will be presented. Preva-
lence of CAC, AAC and cardiac valve calcification at
baseline and their corresponding 95 % CIs will also be
presented.
Secondary analysis
The key secondary analysis will be a comparison of
survival (based on all-cause mortality) between patients
with and without VC based upon the log-rank test
performed at a significance level of 0.05. Hazard ratios
and 95 % CIs will be calculated by a Cox proportional
hazard regression model. In addition, the multivariable
Cox proportional hazard regression model will be per-
formed, using the stepwise method (p <0.05 as the inclu-
sion criteria and p <0.10 as the exclusion criteria),
considering with or without VC as the independent vari-
able and the baseline variables with p <0.25 in univariate
analysis as covariates, and hazard ratios and 95 % CIs for
each factor will be presented. The same analyses will also
be done for survival (based on CVD mortality) and non-
fatal CV event free survival. For each of the above end-
points, the separate comparisons of patients with CAC,
with AAC, with cardiac valve calcification to patients
without VC will be made at a significance level of 0.05.
Association between disease management (including
serum level of calcium, phosphorus and iPTH, and
medications), 25-OH Vit D, FGF23, and all-cause/CVD
mortality, non-fatal CV events will be identified with
Cox proportional hazard regression model, considering
disease management as the independent variables. Asso-
ciations will be tested using the Wald test and described
through the hazard ratios and 95 % CIs.
Association between disease management, 25-OH
Vit D, FGF23, ankle-brachial index (ABI), and LVMI/
LVH and the occurrence of CAC, AAC and cardiac
valve calcification at baseline will be identified with the
logistic regression model. The univariate logistic regres-
sion model will be performed separately, considering
disease management, ABI, and LVMI/LVH as independ-
ent variables. Associations will be tested using the
Wald test and described through the odds ratios and
95 % CIs.
Association between disease management, 25-OH
Vit D, FGF23, ABI, and LVMI/LVH and severities
(scores) of CAC, AAC and cardiac valve calcification at
baseline will be identified with the linear regression
model, considering disease management, ABI, and LVMI/
LVH as independent variables.
Association between CAC progression and disease
management, 25-OH Vit D, FGF23, ABI, as well as
LVMI/LVH will be evaluated by ANCOVA as continu-
ous variables and evaluated by ordinal multinomial logis-
tic regression as categorical variables.
Receiver operating characteristic curve (ROC curve) will
be performed to assess the ability of the CCI to predict the
presence of CAC (lesion score ≥100, ≥400 or ≥1000), with
the area under the curve (AUC), positive and negative
likelihood ratios calculated.
Interim analysis
After the last patient is enrolled and all the baseline data
including calcification status are collected, the data
management committee will perform an interim analysis
to evaluate all baseline data.
Ethical considerations
This study will be conducted in accordance with the prin-
ciples established by the 18th World Medical Assembly
(Helsinki, 1964) and all subsequent amendments. The
study was approved by institutional review boards of all
participating centers and registered with the Chinese
Clinical Trial Registry (ChiCTR-OCH-14004447 at http://
www.chictr.org/en/). Written informed consent for par-
ticipation in the study will be obtained from all partici-
pants. Ethical approvals are provided by all participating
centers.
Determination of sample size
From the latest published annual data, the mortality rate of
Chinese CKD dialysis patients is approximately 10 %, so we
assume the 2-year mortality rate for Chinese CKD dialysis
patients is around 20 % [24]. Assuming the ratio between pa-
tients with and without VC is 7:3, a two-sided log rank test
with an overall sample size of 1520 subjects (of which 1064
are in the VC group and 456 are in the non-VC group)
achieves 80 % power at a 0.05 significance level to detect a
difference of 0.07 between 0.79 and 0.86—the proportions sur-
viving in VC groups and without VC group, respectively. This
corresponds to a hazard ratio of 0.6398. The proportion of
patients lost during follow-up is predicted to be 20 %. These
results are based on the assumption that the hazard rates are
proportional. Therefore, 1520 subjects are to be recruited.
Discussion
VC is a major contributor to CVD, which is a significant
cause of mortality in ESRD. However, the burden and
management of VC in Chinese patients with CKD on
dialysis are still unknown. Given that clinical trials are
considered the best way to provide evidence and related
knowledge for guidance, it is necessary to design a high
quality national observational study that is capable of
addressing these issues.
Liu et al. BMC Nephrology  (2015) 16:129 Page 5 of 7
The CDCS is a uniquely-designed observational cohort
study seeking to collect detailed clinical, biochemical
and laboratory data to inform the prevalence and impact
of management of VC in Chinese patients with CKD on
dialysis, and test the hypothesis that baseline VC is a
predictor for all-cause/CVD mortality and non-fatal CV
events. This study aimed to recruit well-characterized
patients in order to avoid incidence-prevalence bias, and
the sample size will be large enough to achieve multiple
study objectives with adequate variability [25].
This study may be limited by the nature of the design as
an observational study, in comparison with randomized
controlled trials which can commonly provide stronger
evidence in the efficacy of therapies. Since the proportion
of patients receiving HD or PD cannot be predefined, the
strength of comparing the outcome between the two
groups may be weakened. In addition, collection of some
prognostic factors (e.g., brain natriuretic peptide and
troponin) for CVD was not included in the study design as
these tests will not be applicable for every enrolled patient
in the real-world clinical practice setting.
In conclusion, as the first large-scale Chinese cohort
study of patients with CKD on dialysis, the CDCS will
utilize unique data for VC prevalence, demographic
characteristics and disease management of the Chinese
dialysis population to supplement the limitation of cur-
rently available data. The new results gained from the
CDCS will provide increasing awareness of the import-
ance of calcium balance and the risks of calcification, en-
able better clinical decisions and outcomes in assessing
VC and management of serum phosphorus, calcium and
iPTH in Chinese CKD patients on dialysis for nephrolo-
gists and health care providers, and be supportive for
new clinical trials among Chinese CKD patients in the
future. Further analysis of this cohort and comparison
with other cohort studies in western countries might
provide useful insight regarding race discrepancies on
VC and related disease management in CKD patients.
Trial status
This trial is still recruiting on the day of submission.
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